Phil Low (IMAGE)
Caption
An imaging agent just approved by the FDA will allow surgeons to identify additional cancerous lesions, which otherwise would have been left behind, in up to 24% more patients during non-small cell lung cancer surgery. Philip Low, Purdue University’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, is an inventor of the foundational intellectual property upon which the drug is based.
Credit
Rebecca McElhoe / Purdue University
Usage Restrictions
None
License
Original content